TRIALS
VELODROME: evaluation of the efficacy, safety, and pharmacokinetics of ranibizumab via PDS in patients with AMD
STATUS:
DESCRIPTION
The study will evaluate the efficacy, safety, and pharmacokinetics of ranibizumab 100 mg/mL delivered through a continuous delivery device (PDS) refilled every 36 weeks compared to a refill every 24 weeks in patients with neovascular age-related macular degeneration (nAMD).
Objectives
The primary objective of this study is to evaluate the efficacy of ranibizumab 100 mg/mL delivered through the PDS every 36 weeks compared to every 24 weeks.
Population
Patients over 50 years of age diagnosed with neovascular AMD within the 9 months prior to the screening visit.
They must have received a minimum of 3 injections in the last 6 months with demonstrated efficacy. If this treatment requirement is not met, the patient may enter a pre-study phase during which treatment will be administered until the minimum number of prior injections is achieved before entering the study.
Duration
Associated Pathologies
No results found.
If you found this interesting, feel free to share it here: